论文部分内容阅读
目的探讨不同方案的沙利度胺对多发性骨髓瘤患者在治疗过程中的临床疗效以及相关不良反应。方法以确诊为多发性骨髓瘤的患者100例为研究对象,随机分为观察组和对照组,每组50例。对照组应用低剂量沙利度胺进行治疗,观察组患者应用高剂量沙利度胺联合VAD化疗方案,2组患者在不同的治疗方案治疗后,比较患者的疗效、并发症的发生情况、观察指标的动态变化及患者对治疗的满意度情况,同时对2组患者出现的相关不良反应进行分析。结果 2组患者经过两种不同组合的治疗方案后,病情不同程度的得到的控制,观察组患者的治疗总有效率高于对照组(P<0.05),对照组患者的并发症发生率明显高于观察组(P<0.05),观察组患者的满意程度评分优于对照组患者的满意程度评分(P<0.05)。观察组的患者经过治疗后β微球蛋白、尿素氮水平及骨髓浆细胞计数均低于对照组(P<0.05),血红蛋白水平高于对照组(P<0.05)。结论作为一种治疗多发性骨髓瘤的有效药物,沙利度胺能够在实际的对多发性骨髓瘤患者进行治疗,但在实际的治疗过程中,使用低剂量沙利度胺对患者进行治疗的效果往往不佳,通过使用高剂量沙利度胺联合VAD化疗的方式能够显著提高疗效,同时能够降低患者的并发症,在临床治疗多发性骨髓瘤患者的过程中值得推广应用。
Objective To investigate the clinical efficacy of thalidomide with different regimens in the treatment of multiple myeloma and the related adverse reactions. Methods 100 patients diagnosed as multiple myeloma were randomly divided into observation group and control group, 50 cases in each group. The control group was treated with low-dose thalidomide. Patients in the observation group were treated with high-dose thalidomide combined with VAD chemotherapy. Two groups of patients were treated with different treatment regimens to compare the efficacy and complications of the two groups. Dynamic changes in indicators and patient satisfaction with the treatment, while the two groups of patients related adverse reactions were analyzed. Results The two groups of patients after two different combinations of treatment options, the disease was controlled to varying degrees, the observation group patients with total effective rate was higher than the control group (P <0.05), the control group was significantly higher incidence of complications In the observation group (P <0.05), the satisfaction score of the observation group was better than that of the control group (P <0.05). The levels of β-microglobulin, urea nitrogen and bone marrow plasma cells in the observation group were lower than those in the control group (P <0.05) and hemoglobin levels were higher than those in the control group (P <0.05). Conclusion As an effective drug for the treatment of multiple myeloma, thalidomide can actually treat patients with multiple myeloma, but in the actual treatment, patients treated with low-dose thalidomide The effect is often poor. The combination of high-dose thalidomide and VAD chemotherapy can significantly improve the curative effect and reduce the complication of patients. Therefore, it is worthy of popularization and application in the treatment of patients with multiple myeloma.